Recent News

• 06.25.2026 - ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
• 06.25.2026 - ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
• 06.25.2026 - ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
• 06.25.2026 - ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
• 04.30.2026 - ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
• 04.08.2026 - ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
• 04.08.2026 - ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
• 03.12.2026 - ProQR Announces Year End 2025 Operating and Financial Results
• 03.12.2026 - ProQR Announces Year End 2025 Operating and Financial Results
• 03.03.2026 - ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

Recent Filings

• 06.30.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 06.30.2026 - 4/A Statement of changes in beneficial ownership of securities
• 06.30.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.26.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.26.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 06.26.2026 - EX-99.1 EX-99.1
• 06.25.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.25.2026 - EX-99.1 EX-99.1
• 06.03.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 06.03.2026 - 4 Statement of changes in beneficial ownership of securities